# Regeneron Pharmaceuticals operating income entity: /record/regeneron-pharmaceuticals.md predicate: operating_income page: /record/regeneron-pharmaceuticals/operating_income as_of: 2026-11-09 cite: AsOf. "Regeneron Pharmaceuticals quarterly operating income: 2,048,200,000 United States dollar", as of 2026-09-30. Claim clm_4585DB96888D, https://asof.is/claim/clm_4585DB96888D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm. As of November 9, 2026, the latest operating income figure on the AsOf record for Regeneron Pharmaceuticals is $2.05 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Regeneron Pharmaceuticals's latest full-year operating income is $3.58 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 18 claims on Regeneron Pharmaceuticals's operating income, 1 open and 17 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest operating income The newest figure for a shorter period, the quarter ended September 30, 2026: a quarterly_operating_income claim, kept apart from the full-year series. - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_operating_income | 2,048,200,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_4585DB96888D](/claim/clm_4585DB96888D.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm ## Latest full-year operating income What the record asserts on 2026-11-09. - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 3,577,900,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_1B456AFB0CC5](/claim/clm_1B456AFB0CC5.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | -86,249,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_C6F910B9B23D](/claim/clm_C6F910B9B23D.md) | [clm_3E8FF1B94F70](/claim/clm_3E8FF1B94F70.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | -74,103,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_244D0F6FC089](/claim/clm_244D0F6FC089.md) | [clm_C6F910B9B23D](/claim/clm_C6F910B9B23D.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | -97,472,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_E89A362E23D2](/claim/clm_E89A362E23D2.md) | [clm_244D0F6FC089](/claim/clm_244D0F6FC089.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000120677411000263/0001206774-11-000263-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | -205,159,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_38E3B92F967E](/claim/clm_38E3B92F967E.md) | [clm_E89A362E23D2](/claim/clm_E89A362E23D2.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000120677412000709/0001206774-12-000709-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 457,713,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_8A99CD2AC1DF](/claim/clm_8A99CD2AC1DF.md) | [clm_38E3B92F967E](/claim/clm_38E3B92F967E.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217613000004/0001532176-13-000004-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 760,028,000 United States dollar | valid 2013-12-31 to 2014-12-31 | conf 0.95 | superseded | superseded_by [clm_BFC64F70A0E6](/claim/clm_BFC64F70A0E6.md) | [clm_8A99CD2AC1DF](/claim/clm_8A99CD2AC1DF.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217614000008/0001532176-14-000008-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 838,431,000 United States dollar | valid 2014-12-31 to 2015-12-31 | conf 0.95 | superseded | superseded_by [clm_83526134FED4](/claim/clm_83526134FED4.md) | [clm_BFC64F70A0E6](/claim/clm_BFC64F70A0E6.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217615000008/0001532176-15-000008-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 1,251,916,000 United States dollar | valid 2015-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_1B4689E225C8](/claim/clm_1B4689E225C8.md) | [clm_83526134FED4](/claim/clm_83526134FED4.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/0001532176-16-000045-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 1,330,741,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_C3B4B1FC7983](/claim/clm_C3B4B1FC7983.md) | [clm_1B4689E225C8](/claim/clm_1B4689E225C8.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217617000008/0001532176-17-000008-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 2,079,591,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_B9BD4A691253](/claim/clm_B9BD4A691253.md) | [clm_C3B4B1FC7983](/claim/clm_C3B4B1FC7983.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 2,534,400,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_1E47F3A48E8B](/claim/clm_1E47F3A48E8B.md) | [clm_B9BD4A691253](/claim/clm_B9BD4A691253.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217619000009/0001532176-19-000009-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 2,209,800,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_B1B09D53441E](/claim/clm_B1B09D53441E.md) | [clm_1E47F3A48E8B](/claim/clm_1E47F3A48E8B.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 3,576,600,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_C2D9EB28F08E](/claim/clm_C2D9EB28F08E.md) | [clm_B1B09D53441E](/claim/clm_B1B09D53441E.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000180422021000008/0001804220-21-000008-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 8,946,800,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_1DC3E40C4DC4](/claim/clm_1DC3E40C4DC4.md) | [clm_C2D9EB28F08E](/claim/clm_C2D9EB28F08E.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 4,738,900,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_5B0035249BB7](/claim/clm_5B0035249BB7.md) | [clm_1DC3E40C4DC4](/claim/clm_1DC3E40C4DC4.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 4,047,100,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_398CD3D76930](/claim/clm_398CD3D76930.md) | [clm_5B0035249BB7](/claim/clm_5B0035249BB7.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 3,990,700,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_1B456AFB0CC5](/claim/clm_1B456AFB0CC5.md) | [clm_398CD3D76930](/claim/clm_398CD3D76930.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm - [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | operating_income | 3,577,900,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_1B456AFB0CC5](/claim/clm_1B456AFB0CC5.md) sources: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm ## What replaced what - -$86.25 million (2008-12-31 to 2009-12-31, [clm_3E8FF1B94F70](/claim/clm_3E8FF1B94F70.md)) was replaced by -$74.1 million from 2009-12-31 ([clm_C6F910B9B23D](/claim/clm_C6F910B9B23D.md)) - -$74.1 million (2009-12-31 to 2010-12-31, [clm_C6F910B9B23D](/claim/clm_C6F910B9B23D.md)) was replaced by -$97.47 million from 2010-12-31 ([clm_244D0F6FC089](/claim/clm_244D0F6FC089.md)) - -$97.47 million (2010-12-31 to 2011-12-31, [clm_244D0F6FC089](/claim/clm_244D0F6FC089.md)) was replaced by -$205.16 million from 2011-12-31 ([clm_E89A362E23D2](/claim/clm_E89A362E23D2.md)) - -$205.16 million (2011-12-31 to 2012-12-31, [clm_E89A362E23D2](/claim/clm_E89A362E23D2.md)) was replaced by $457.71 million from 2012-12-31 ([clm_38E3B92F967E](/claim/clm_38E3B92F967E.md)) - $457.71 million (2012-12-31 to 2013-12-31, [clm_38E3B92F967E](/claim/clm_38E3B92F967E.md)) was replaced by $760.03 million from 2013-12-31 ([clm_8A99CD2AC1DF](/claim/clm_8A99CD2AC1DF.md)) - $760.03 million (2013-12-31 to 2014-12-31, [clm_8A99CD2AC1DF](/claim/clm_8A99CD2AC1DF.md)) was replaced by $838.43 million from 2014-12-31 ([clm_BFC64F70A0E6](/claim/clm_BFC64F70A0E6.md)) - $838.43 million (2014-12-31 to 2015-12-31, [clm_BFC64F70A0E6](/claim/clm_BFC64F70A0E6.md)) was replaced by $1.25 billion from 2015-12-31 ([clm_83526134FED4](/claim/clm_83526134FED4.md)) - $1.25 billion (2015-12-31 to 2016-12-31, [clm_83526134FED4](/claim/clm_83526134FED4.md)) was replaced by $1.33 billion from 2016-12-31 ([clm_1B4689E225C8](/claim/clm_1B4689E225C8.md)) - $1.33 billion (2016-12-31 to 2017-12-31, [clm_1B4689E225C8](/claim/clm_1B4689E225C8.md)) was replaced by $2.08 billion from 2017-12-31 ([clm_C3B4B1FC7983](/claim/clm_C3B4B1FC7983.md)) - $2.08 billion (2017-12-31 to 2018-12-31, [clm_C3B4B1FC7983](/claim/clm_C3B4B1FC7983.md)) was replaced by $2.53 billion from 2018-12-31 ([clm_B9BD4A691253](/claim/clm_B9BD4A691253.md)) - $2.53 billion (2018-12-31 to 2019-12-31, [clm_B9BD4A691253](/claim/clm_B9BD4A691253.md)) was replaced by $2.21 billion from 2019-12-31 ([clm_1E47F3A48E8B](/claim/clm_1E47F3A48E8B.md)) - $2.21 billion (2019-12-31 to 2020-12-31, [clm_1E47F3A48E8B](/claim/clm_1E47F3A48E8B.md)) was replaced by $3.58 billion from 2020-12-31 ([clm_B1B09D53441E](/claim/clm_B1B09D53441E.md)) - $3.58 billion (2020-12-31 to 2021-12-31, [clm_B1B09D53441E](/claim/clm_B1B09D53441E.md)) was replaced by $8.95 billion from 2021-12-31 ([clm_C2D9EB28F08E](/claim/clm_C2D9EB28F08E.md)) - $8.95 billion (2021-12-31 to 2022-12-31, [clm_C2D9EB28F08E](/claim/clm_C2D9EB28F08E.md)) was replaced by $4.74 billion from 2022-12-31 ([clm_1DC3E40C4DC4](/claim/clm_1DC3E40C4DC4.md)) - $4.74 billion (2022-12-31 to 2023-12-31, [clm_1DC3E40C4DC4](/claim/clm_1DC3E40C4DC4.md)) was replaced by $4.05 billion from 2023-12-31 ([clm_5B0035249BB7](/claim/clm_5B0035249BB7.md)) - $4.05 billion (2023-12-31 to 2024-12-31, [clm_5B0035249BB7](/claim/clm_5B0035249BB7.md)) was replaced by $3.99 billion from 2024-12-31 ([clm_398CD3D76930](/claim/clm_398CD3D76930.md)) - $3.99 billion (2024-12-31 to 2025-12-31, [clm_398CD3D76930](/claim/clm_398CD3D76930.md)) was replaced by $3.58 billion from 2025-12-31 ([clm_1B456AFB0CC5](/claim/clm_1B456AFB0CC5.md)) ## Questions this record answers ### What is Regeneron Pharmaceuticals's current operating income? The latest figure on the record is $2.05 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $3.58 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 9, 2026. ### What was Regeneron Pharmaceuticals's operating income for the quarter ended September 30, 2026? $2.05 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Regeneron Pharmaceuticals's operating income last change? The latest value on the record is $3.58 billion, dated December 31, 2025; before it the record holds $3.99 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Regeneron Pharmaceuticals's operating income before $3.58 billion? $3.99 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/regeneron-pharmaceuticals/operating_income (markdown: /record/regeneron-pharmaceuticals/operating_income.md) - Entity twin: /record/regeneron-pharmaceuticals.md ยท timeline: /timelines/regeneron-pharmaceuticals.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.